The city of Boston, Massachusetts, currently has 464 active clinical trials seeking participants for Cancer research studies.
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
NCT03797391
Recruiting
First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2023
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
Register for Updates
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
NCT04485286
Recruiting
The goal of this study is to investigate the efficacy of \[68Ga\]CBP8 to detect collagen deposition in radiation induced tissue injury.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/30/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Lung Cancer, Radiation Fibrosis, Radiation Induced Lung Injury, Pancreas Cancer
Register for Updates
Patient-Centered Surgical Prehabilitation
NCT05715684
Recruiting
The purpose of this research is to validate the prehabilitation program which is defined as a set of interventions meant to prepare the body physically and nutritionally for the cystectomy procedure.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/20/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Bladder Cancer, Cystectomy
Register for Updates
The Genomic Medicine at VA Study
NCT04331535
Recruiting
This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, atrial fibrillation, type 2 diabetes mellitus, colorectal cancer, breast cancer, or prostate cancer), measured by time-to-diagnosis of prevalent or incident disease over 24 months.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
09/29/2022
Locations: VA Boston Healthcare System, Boston, Massachusetts
Conditions: Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
Register for Updates
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
NCT03482102
Recruiting
This research study is studying a combination of drugs as a possible treatment for Hepatocellular Carcinoma or Biliary Tract Cancer. The interventions involved in this study are: * Durvalumab * Tremelimumab * Radiation Therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Hepatocellular Carcinoma, Biliary Tract Cancer
Register for Updates
Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT03104439
Recruiting
This research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer. The interventions involved in this study are: * Nivolumab * Ipilimumab * Radiation Therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Massachusetts general Hospital, Boston, Massachusetts
Conditions: Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, MSI High Colorectal Cancer
Register for Updates
Folfox+Irinotecan+Chemort In Esophageal Cancer
NCT04656041
Recruiting
In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: - Liposomal irinotecan
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates